Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting. (2:18)
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC. (3:18)
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC). (2:06)
Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data should be applied in clinical practice. (4:37)
Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-invasive, advanced bladder cancer. (2:58)
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder. (1:57)
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (1:40)
Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? (3:34)
How do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046)
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1. (9:06)